Yayınlar & Eserler

Yayın Ağı
Makaleler 45
Tümü (45)
SCI-E, SSCI, AHCI (42)
SCI-E, SSCI, AHCI, ESCI (42)
Scopus (45)
TRDizin (3)

1. Pan‑immune‑inflammation value as a prognostic and predictive biomarker in metastatic non‑small cell lung cancer treated with nivolumab: A real‑world study

TURAN N., Yildiz H. S., Yildirim S., Turkoglu E., Ozkeım U., Oksuz S., et al.
Oncology Letters , cilt.32, sa.3, 2026 (SCI-Expanded, Scopus) Creative Commons License

2. Correlation between F-18 FDG PET/CT-derived metabolic parameters and PD-L1 expression in non-small cell lung cancer patients Correlación entre los parámetros metabólicos derivados de la PET/TC con [18F]FDG y la expresión de PD-L1 en pacientes con cáncer de pulmón no microcítico

Kesim S., ÖZÜLKER F., Gecmen G. G., TURAN N.
Revista Espanola de Medicina Nuclear e Imagen Molecular , cilt.45, sa.4, 2026 (SCI-Expanded, Scopus)

3. Prognostic Significance of Preoperative PET-CT SUVmax in Resected Non-Small Cell Lung Cancer: A Single-Center Retrospective Study

Yaşar A., Yaşar Z. Y., Yıldırım S., Doğan A., KAYA T., Aydoğan M., et al.
Medicina (Lithuania) , cilt.62, sa.6, 2026 (SCI-Expanded, Scopus)

4. Impact of Peri-Immunotherapy Antibiotic Exposure on Survival Outcomes in Metastatic Renal Cell Carcinoma: A Real-World IMDC Risk–Stratified Analysis

Oksuz S., Kinikoglu O., Ozkerim U., Isik D., Surmeli H., Ay S., et al.
Journal of Clinical Medicine , cilt.15, sa.5, 2026 (SCI-Expanded, Scopus)

5. Association Between Body Mass Index and Clinical Outcomes of CDK4/6 Inhibitors in HR+/HER2− Metastatic Breast Cancer: A Real-World Cohort Study

Orman S., Aydoğan M., Sarıyar Busery N., Yıldırım S., Yıldız H. Ş., Bal H., et al.
Journal of Clinical Medicine , cilt.15, sa.4, 2026 (SCI-Expanded, Scopus)

6. Prognostic Impact and Clinicopathological Correlates of HER2 Status in Gastric Cancer: A Multicenter Retrospective Turkish Oncology Group Study

Yildirim S., SEVER Ö. N., Turkoglu E., Sariyar Busery N., Dogan A., Baydas T., et al.
Clinical Medicine Insights: Oncology , cilt.20, 2026 (SCI-Expanded, Scopus)

7. Prognostic Value of the Cancer Inflammation Prognostic Index (CIPI) in De Novo Metastatic Colon Cancer: A Multicenter Retrospective Cohort Study

Doğan A., Yıldırım S., Erölmez H. N., Akdağ G., Yıldız H. Ş., Yüksel Yaşar Z., et al.
Cancer Control , cilt.33, 2026 (SCI-Expanded, Scopus)

8. Development of a Machine Learning-Based Prognostic Model Using Systemic Inflammation Markers in Patients Receiving Nivolumab Immunotherapy: A Real-World Cohort Study

Ozkerim U., Isik D., Kinikoglu O., Oksuz S., Altintas Y. E., Akdag G., et al.
Journal of Personalized Medicine , cilt.16, sa.1, 2026 (Scopus)

9. Efficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study)

Erol C., Zeynelgil E., Hizal M., Dumludag A., Erciyestepe M., Kalaci E., et al.
Clinical and Translational Oncology , 2026 (SCI-Expanded, Scopus)

10. Significance of CEA Dynamics and Systemic Inflammatory Markers in HER2-Positive Metastatic Colorectal Cancer Patients Undergoing First-Line Chemotherapy: A Real-World Cohort Study

Ozkerim U., Kinikoglu O., Oksuz S., Isik D., Altintas Y. E., Yildirim S., et al.
Medicina (Lithuania) , cilt.62, sa.1, 2026 (SCI-Expanded, Scopus)

11. Prognostic Impact of Tumor Size in Patients with Stage T3N1 Colon Cancer

Turkoglu E., Sarıyar Busery N., Yildirim S., Akdağ Topal G., Salman C. B., Conay E., et al.
Journal of Clinical Medicine , cilt.15, sa.1, 2026 (SCI-Expanded, Scopus)

12. Association Between Time to PSA Nadir, Radiologic Progression, and PSA Progression in mHSPC Patients Treated with Abiraterone or Enzalutamide

Ozkerim U., Kinikoglu O., Isik D., Altintas Y. E., Ay Ersoy S., Surmeli H., et al.
Journal of Clinical Medicine , cilt.15, sa.1, 2026 (SCI-Expanded, Scopus)

13. Adjuvant Chemotherapy and Chemoradiotherapy in Gastric Cancer: Prognostic Determinants and Real-World Survival Outcomes

Yildirim S., ODABAŞ H., Ay Ersoy S., Orman S., Aydogan M., Turkoglu E., et al.
Journal of Clinical Medicine , cilt.15, sa.2, 2026 (SCI-Expanded, Scopus)

14. Association between GRIm score and response to nivolumab monotherapy in patients with advanced malignant melanoma

Oksuz S., Kinikoglu O., Ozkerim U., Isik D., Surmeli H., Ay S., et al.
Journal of Cancer Research and Clinical Oncology , cilt.152, sa.1, 2026 (SCI-Expanded, Scopus)

15. Efficacy of Palbociclib and Ribociclib in Second-line Treatment of Metastatic Hormone Receptor-positive Breast Cancer: A Single-center Experience

Yildirim S., SEVER Ö. N., Akdaĝ Topal G., Orman S., Aydoĝan M., Türkoĝlu E., et al.
Journal of Oncological Science , cilt.11, sa.3, ss.224-232, 2025 (Scopus, TRDizin)

16. The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis

Yıldırım S., Başoğlu T., Doğan A., Akdağ G., Kınıkoğlu O., Topal A., et al.
BMC Cancer , cilt.25, sa.1, 2025 (SCI-Expanded, Scopus)

17. The Effect of the Clinical-Pathological CPS+EG Staging System on Survival Outcomes in Patients with HER2-Positive Breast Cancer Receiving Neoadjuvant Treatment: A Retrospective Study

Orman S., Aydoğan M., Kınıkoğlu O., Yıldırım S., Sarıyar Busery N., Yıldız H. Ş., et al.
Medicina (Lithuania) , cilt.61, sa.10, 2025 (SCI-Expanded, Scopus) Creative Commons License

18. Triple-Negative Apocrine Carcinoma: Largest Cohort Highlights Unique Biology and Survival Advantage

Basoglu T., Ozkerim U., Oksuz S., Kinikoglu O., Yildirim S., Kokten S., et al.
Journal of Clinical Medicine , cilt.14, sa.19, 2025 (SCI-Expanded, Scopus) Creative Commons License

19. Effect of Family and Personal Medical History on Treatment Outcomes of Tyrosine Kinase Inhibitors (TKIs) in Non-Small Cell Lung Cancer (NSCLC)

Surmeli H., Turkoglu E., Isik D., Kinikoglu O., Altintas Y. E., Ozkerim U., et al.
Healthcare (Switzerland) , cilt.13, sa.15, 2025 (SCI-Expanded, SSCI, Scopus) Creative Commons License

20. Comparison of paclitaxel and docetaxel in dual HER2 blockade: efficacy and safety in neoadjuvant treatment of HER2-positive breast cancer

Turkoglu E., Akdag Topal G., Yildirim S., Kinikoglu O., Sariyar Busery N., Aydogan M., et al.
Breast Cancer Research and Treatment , cilt.211, sa.3, ss.743-752, 2025 (SCI-Expanded, Scopus)

21. The Association of Khorana Risk Score with Venous Thromboembolism and Overall Survival in Patients with Metastatic Gastric Cancer

Turkoglu E., Topal G. A., Yıldırım S., Kınıkoglu O., Sarıyar Busery N., KAYA T., et al.
Medicina (Lithuania) , cilt.61, sa.6, 2025 (SCI-Expanded, Scopus) Creative Commons License

22. The frequency of driver mutations in non-small cell lung cancer patients: The Turkish nation-wide, observational, Registurk-Lung study (updated analysis).

TURAN N., ÇİL T., Artac M., Hacibekiroglu I., Sümbül A. T., Uncu D., et al.
Journal of Clinical Oncology , cilt.43, 2025 (SCI-Expanded, Scopus)

23. Impact of Age and Menopausal Status on T-DM1 (Ado-Trastuzumab Emtansine) Treatment Outcomes in HER2-Positive Breast Cancer

Surmeli H., Isik D., Kinikoglu O., Altintas Y. E., Ozkerim U., Oksuz S., et al.
Pharmaceuticals , cilt.18, sa.6, 2025 (SCI-Expanded, Scopus) Creative Commons License

24. Impact of HER2 Status Assessed by Immunohistochemistry on Treatment Response in Patients with Metastatic Breast Cancer Receiving Trastuzumab Emtansine

Oksuz S., Kinikoglu O., Ozkerim U., Altintas Y. E., Isik D., Surmeli H., et al.
Medicina (Lithuania) , cilt.61, sa.5, 2025 (SCI-Expanded, Scopus) Creative Commons License

25. Impact of Metastasectomy on Survival Outcomes in Colorectal Cancer: A Single Center Retrospective Study

Kınıkoğlu O., Altıntaş Y. E., Akdağ G., Yıldırım S., Yıldız H. Ş., Doğan A., et al.
Acta Haematologica Oncologica Turcica , cilt.58, sa.1, ss.40-45, 2025 (Scopus, TRDizin)

26. Tumor-infiltrating lymphocytes as predictive biomarkers in neoadjuvant treatment of HER2-positive breast cancer

Kınıkoğlu O., Altıntaş Y. E., Yıldız A., Akdağ G., Bal H., Yaşar Z. Y., et al.
Oncologist , cilt.30, sa.4, 2025 (SCI-Expanded, Scopus)

27. Efficacy and Clinical Outcomes of Crizotinib in Patients with ROS1-Rearranged NSCLC: A Multicenter Study

Topal A., Akdag G., Yildirim S., Kinikoglu O., Isik D., Yildirim G., et al.
Medicina (Lithuania) , cilt.61, sa.3, 2025 (SCI-Expanded, Scopus)

28. Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study

Beypınar İ., Demir H., YASLIKAYA Ş., KÖŞECİ T., Demir B., Çolak G., et al.
Breast Cancer Research and Treatment , cilt.208, sa.3, ss.597-604, 2024 (SCI-Expanded, Scopus)

29. The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy

Yildirim S., Dogan A., Akdag G., Yüksel Yasar Z., Bal H., Kinikoglu O., et al.
Scientific Reports , cilt.14, sa.1, 2024 (SCI-Expanded, Scopus)

30. Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases

Kahraman S., KARAKAYA S., Kaplan M. A., SEZGİN GÖKSU S., Ozturk A., Isleyen Z. S., et al.
Scientific Reports , cilt.14, sa.1, 2024 (SCI-Expanded, Scopus)

31. Evaluating the Effectiveness of Nivolumab in Metastatic Lung Cancer Among Patients Aged 65 and Older

Isik D., ALAN Ö., Akdağ G., Yildirim S., Kınıkoğlu O., Altintas Y. E., et al.
Journal of Clinical Medicine , cilt.13, sa.20, 2024 (SCI-Expanded, Scopus) Creative Commons License

32. What alters prognosis in patients who were operated for lung cancer with lymph node metastasis?

ÇİMENOĞLU R. B., Ozdemir A., Buz M., Dogruyol T., TURAN N., DEMİRHAN R.
ANZ Journal of Surgery , cilt.94, sa.10, ss.1781-1786, 2024 (SCI-Expanded, Scopus)

33. Prognostic Impact and Clinical Features of Spread through Air Spaces in Operated Lung Cancer: Real-World Analysis

Yildirim S., ALAN Ö., Yuksel Yasar Z., KAYA T., Akdag G., Kinikoglu O., et al.
Medicina (Lithuania) , cilt.60, sa.8, 2024 (SCI-Expanded, Scopus) Creative Commons License

34. A Novel Prognostic Indicator for Immunotherapy Response: Lymphocyte-to-Albumin (LA) Ratio Predicts Survival in Metastatic NSCLC Patients

Yildirim S., Dogan A., Akdag G., Cavdar E., Kinikoglu O., Oksuz S., et al.
Cancers , cilt.16, sa.14, 2024 (SCI-Expanded, Scopus)

35. Clinical Effectiveness of Targeted Therapies Following Nivolumab Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-World Study

Işık D., Kınıkoğlu O., Akdağ G., Altıntaş Y. E., Türkoğlu E., Yildirim S., et al.
Medicina (Lithuania) , cilt.60, sa.7, 2024 (SCI-Expanded, Scopus) Creative Commons License

36. Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer

Kınıkoğlu O., ODABAŞ H., Altıntaş Y. E., Yıldız A., Çakan B., Akdağ G., et al.
Medicina (Lithuania) , cilt.60, sa.6, 2024 (SCI-Expanded, Scopus)

37. Neoadjuvant Chemotherapy and Pathologic Complete Response in HR+/HER2− Breast Cancer: Impact of Tumor Ki67 and ER Status

Akdag G., Yildirim S., Dogan A., Yasar Z. Y., Bal H., Kinikoglu O., et al.
Chemotherapy , cilt.69, sa.3, ss.141-149, 2024 (SCI-Expanded, Scopus)

38. Prognostic scores in pulmonary large cell neuroendocrine carcinoma: A retrospective cohort study

Akdag G., ALAN Ö., Dogan A., Yildirim S., Kinikoglu O., Batu A., et al.
Heliyon , cilt.10, sa.3, 2024 (SCI-Expanded, Scopus)

39. Gustave Roussy Immune Score (GRIm-Score) Predicts Prognosis in Non-Small Cell Lung Cancer Patients Undergoing Nivolumab: A Multicenter Retrospective Study from Turkiye

Majidova N., Yildirim S., Kocaaslan E., Guren A. K., Yildiz H. S., Kircali M. F., et al.
UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.34, sa.4, ss.206-212, 2024 (SCI-Expanded, Scopus, TRDizin)

40. Outcomes of surveillance versus adjuvant treatment for patients with stage-I seminoma: a single-center experience

Akdag G., ALAN Ö., Dogan A., Yuksel Z., Yildirim S., Kinikoglu O., et al.
World Journal of Urology , cilt.41, sa.8, ss.2201-2207, 2023 (SCI-Expanded, Scopus)

41. Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer?

ODABAŞ H., Dogan A., ÖZÇELİK M., Yildirim S., Ozkerim U., TURAN N., et al.
Medicina (Lithuania) , cilt.59, sa.3, 2023 (SCI-Expanded, Scopus)

42. Merkel cell carcinoma in Turkey: A multicentric study

YILDIZ F., DEMİRCİ U., KÜÇÜKARDA A., BÜYÜKŞİMŞEK M., Sakalar T., Topcu T., et al.
Journal of Cancer Research and Therapeutics , cilt.17, sa.6, ss.1525-1529, 2021 (SCI-Expanded, Scopus)

43. Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer?

Ayhan M., Laçin Ş., Özyükseler D. T., Sürmeli H., Doğan A., Turan M., et al.
Journal of Oncology Pharmacy Practice , cilt.27, sa.6, ss.1461-1467, 2021 (SCI-Expanded, Scopus)

44. Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology?

Ayhan M., TURAN N., KÖSTEK O., Tufan G., Tataroğlu Özyükseler D., ODABAŞ H., et al.
Current Problems in Cancer , cilt.45, sa.3, 2021 (SCI-Expanded, Scopus)

45. Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: a single center’s experience

Ayhan M., ODABAŞ H., TURAN N., Ozyukseler D. T., KÖSTEK O., Alkan G., et al.
Journal of Chemotherapy , cilt.33, sa.7, ss.499-508, 2021 (SCI-Expanded, Scopus)
Metrikler

Yayın

45

Yayın (WoS)

42

Yayın (Scopus)

45

H-İndeks (WoS)

6

Atıf (Scopus)

126

H-İndeks (Scopus)

6

Atıf (TrDizin)

1

H-İndeks (TrDizin)

1

Atıf (Diğer Toplam)

1

Tez Danışmanlığı

1

Açık Erişim

10